Physician profile
John Dickson
NPI 1154467116
$7,545.10
in general payments reported to CMS, 2019-2025
56 companies · $619 in 2025
The $619 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,290 · 2020: $1,320 · 2021: $1,436 · 2022: $1,028 · 2023: $617 · 2024: $1,235 · 2025: $619.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,471.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,471.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $921.00 | 2021-2025 | |
| Lilly USA, LLC | $515.14 | 2019-2024 | Jardiance, Mounjaro, Emgality |
| Astrazeneca Pharmaceuticals Lp | $511.98 | 2019-2024 | Airsupra, Farxiga |
| Janssen Pharmaceuticals, INC | $446.05 | 2019-2022 | |
| Abbott Laboratories | $411.27 | 2020-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $395.40 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $346.61 | 2019-2025 | Jardiance, Synjardy |
| Abbvie INC. | $305.82 | 2020-2025 | Qulipta, Ubrelvy |
| Allergan, INC. | $287.87 | 2019-2020 | |
| Esperion Therapeutics, INC. | $262.87 | 2020-2024 | Nexletol |
| Novo Nordisk INC | $246.41 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Amarin Pharma, INC. | $242.67 | 2019-2022 | |
| Bausch Health US, LLC | $240.66 | 2019-2023 | Aplenzin |
| Si-Bone, INC. | $207.68 | 2019-2024 | |
| Teva Pharmaceuticals USA, INC. | $199.75 | 2019-2021 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Dickson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.